SpringWorks Therapeutics, Inc. (SWTX)
| Market Cap | 2.58B |
| Revenue (ttm) | 191.59M |
| Net Income (ttm) | -258.13M |
| Shares Out | 74.92M |
| EPS (ttm) | -3.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,221,103 |
| Open | 35.60 |
| Previous Close | 37.12 |
| Day's Range | 33.27 - 36.17 |
| 52-Week Range | 28.21 - 62.00 |
| Beta | 0.79 |
| Analysts | Strong Buy |
| Price Target | 72.40 (+110.28%) |
| Earnings Date | May 1, 2025 |
About SWTX
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor of MEK1 and MEK2 for the treatment of adult and pediatric patients two years of age and older with neurofibromatosis type 1-associated plexiform neurofi... [Read more]
Financial Performance
In 2024, SpringWorks Therapeutics's revenue was $191.59 million, an increase of 3417.33% compared to the previous year's $5.45 million. Losses were -$258.13 million, -20.60% less than in 2023.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for SWTX stock is "Strong Buy." The 12-month stock price forecast is $72.4, which is an increase of 110.28% from the latest price.
News
Biotech stocks have been hit hard. Why they're a great value now.
Biotech is one of the U.S. stock market's most unloved sectors. But several indicators suggest that a bottom in sentiment could be near, and that's normally a good time to buy.
SpringWorks Therapeutics: Promising Launches, Expanding Pipeline, And M&A Buzz
SpringWorks Therapeutics portfolio features Ogsiveo for desmoid tumors and Gomekli for NF1‑plexiform neurofibromas. In fact, Ogsiveo's revenues alone reached $172 million in 2024, supported by orphan ...
Top 3 Health Care Stocks You May Want To Dump In February
As of Feb. 20, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
– Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO ® (nirogacestat) U.S. net product revenues, respectively –
SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over
- Educational campaign aims to raise awareness and drive conversation about desmoid tumors, the devastating impact they have on patients' lives - STAMFORD, Conn. , Feb. 19, 2025 /PRNewswire/ -- Spring...
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLI™ (mirdametinib), Manufactured By SpringWorks Therapeutics
LOUISVILLE, Ky., Feb. 17, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent specialty pharmacy, has been selected as a national pharmacy partner by SpringWorks Therapeutics, Inc. for...
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment resulted in r...
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment resulted in r...
US FDA approves Springworks' genetic disorder drug
The U.S. Food and Drug Administration on Tuesday approved Springworks Therapeutics' drug to treat a type of rare genetic disorder that causes tumors to grow on nerves throughout the body.
SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025
STAMFORD, Conn., Jan. 30, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announc...
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference
– Achieved $61.5 million and $172.0 million in preliminary fourth quarter and full year 2024 OGSIVEO ® (nirogacestat) U.S. net product revenues, respectively –
SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate
SpringWorks has shown strong revenue growth with OGSIVEO, achieving a 23% increase from Q2 of 2024 to Q3 of 2024, and potential EMA approval if it could boost sales further. Mirdametinib, a MEK inhibi...
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
STAMFORD, Conn., Jan. 03, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announc...
SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great
SpringWorks Therapeutics shows promising growth with their first approved drug and an imminent second approval for mirdametinib in NF1 treatment. SWTX's financials reveal strong cash reserves and grow...
Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks
Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics.
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
STAMFORD, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announc...
SpringWorks Therapeutics, Inc. (SWTX) Q3 2024 Earnings Call Transcript
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q3 2024 Earnings Call November 12, 2024 8:30 AM ET Company Participants Kim Diamond - Vice President, Corporate Communications Saqib Islam - Chief Executi...
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
STAMFORD, Conn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announc...
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
– Achieved $49.3 million in OGSIVEO ® (nirogacestat) net product revenue in the third quarter –
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
– Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in health-related quality of life over the course of mirdametinib treatment ...
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology
– Mirdametinib treatment demonstrated significant confirmed objective response rates and a manageable safety profile in adults and children with NF1-PN –
SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting
– Long-term follow-up data highlight further reductions in tumor size, increase in ORR with additional CRs, sustained improvement in desmoid tumor symptoms, and consistent safety profile, now with a m...
SpringWorks Therapeutics to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
STAMFORD, Conn., Nov. 05, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announc...
SpringWorks Therapeutics Merits A Speculative Buy
Since we last visited with SpringWorks Therapeutics, Inc. in the summer of 2023, the company has garnered its first FDA approval. That drug has seen encouraging initial sales, and management recently ...
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
STAMFORD, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announc...